The Effectiveness of Phytotherapy in SARS-COV2(COVID-19)
NCT ID: NCT04851821
Last Updated: 2023-01-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
80 participants
INTERVENTIONAL
2021-01-04
2021-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Quercetin is extracted from a variety of plant sources, including the onion peel and seeds and pods of Dimorphandra mollis, a tree in the legume family native to South America.
At present, there is no scientific data to demonstrate the effectiveness of herbal medicine, regardless of the plant, to prevent or treat COVID-19. On the other hand, some plant-based food supplements have anti-inflammatory or immunomodulatory properties that may disrupt inflammatory defense mechanisms useful in fighting infections, and in particular against COVID-19.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quercetin In The Treatment Of SARS-COV 2
NCT04853199
Study to Investigate the Clinical Benefits of Dietary Supplement Quercetin for Managing Early Mild Symptoms of COVID-19
NCT04861298
Quercetin in the Prevention of Covid-19 Infection
NCT05037240
Effect of Quercetin on Prophylaxis and Treatment of COVID-19
NCT04377789
Biological Effects of Quercetin in COPD
NCT03989271
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Although we are far from knowing everything about quercetin, its antioxidant, anti-inflammatory, and antihistamine (antiallergic) properties have been observed in numerous in vitro and animal studies.
History on quercetin In 1937, Albert Szent-Gyorgyi received a Nobel Prize for discovering vitamin C and flavonoids, as well as for exploring their biochemical properties. Originally, he gave the flavonoids the name "vitamin P" because of their effectiveness in reducing the permeability of blood vessels. This name was abandoned when it was realized that these substances were not really vitamins.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Quercetix group
Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.
Quercetin
Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.
Placebo Group
Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.
Quercetin
Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quercetin
Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Being over 18 years old
Exclusion Criteria
* Non-consenting patients
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hôpital Universitaire Sahloul
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Riadh Boukef
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Riadh Boukef, professor
Role: PRINCIPAL_INVESTIGATOR
CHU Sahloul, Sousse, Tunisia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Riadh Boukef
Sahloul, Sousse Governorate, Tunisia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Quercetix
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.